Literature DB >> 16219143

[Prognostic analysis of stage III-IV non-small cell lung cancer patients treated by traditional chinese medicine].

Dai-Han Zhou1, Li-Zhu Lin, Yi-Qiang Zhou, Rong-Cheng Luo, Kui-Feng Liu, Ying-Jie Jia, Ji-Yue Chen, Xi-Wei Niu, Bi-Ru Su, Jiang Lu, Shu-Tang Wang.   

Abstract

BACKGROUND &
OBJECTIVE: Chemotherapy is a treatment for stage III-IV non-small cell lung cancer (NSCLC), but the efficacy is not ideal. Traditional Chinese medicine (TCM) has certain effect on NSCLC. This study was to investigate various factors that affect the prognosis of advanced NSCLC, and evaluate the role of TCM in enlonging survival time of patients with stage III-IV NSCLC.
METHODS: The NSCLC patients who meet the inclusive criteria were randomized into TCM group, combination (TCM plus NP regimen) group, and chemotherapy group, and received relevant treatments. The median survival time (MST) was calculated by Kaplan-Meier method. The prognosis of the patients was analyzed by COX regression method.
RESULTS: A total of 294 stage III-IV NSCLC patients were enrolled, of which 99 were in TCM group, 103 in combination group, 92 in chemotherapy group. The MST were 292 days in TCM group, 355 days in combination group, and 236 days in chemotherapy group; the cumulative survival rates were 45.38%, 48.86%, and 42.17%, respectively (P>0.05). Cox regression analysis indicated that therapy, gender, disease course, erythrocyte sedimentation, KPS score, tumor size, and patient's weight were independent prognostic factors of stage III-IV NSCLC.
CONCLUSION: Compare with chemotherapy alone, TCM combined with chemotherapy may prolong the survival time of stage III-IV NSCLC patients.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16219143

Source DB:  PubMed          Journal:  Ai Zheng


  4 in total

1.  Efficacy of Aidi Injection () on overexpression of P-glycoprotein induced by vinorelbine and cisplatin regimen in patients with non-small cell lung cancer.

Authors:  Jun-Jie Ma; Hui-Ping Liu
Journal:  Chin J Integr Med       Date:  2016-08-02       Impact factor: 1.978

2.  Long-Term Effectiveness of Combined Treatment with Traditional Chinese Medicine and Western Medicine on the Prognosis of Patients with Lung Cancer.

Authors:  Woung-Ru Tang; Sien-Hung Yang; Chih-Teng Yu; Chin-Chou Wang; Sheng-Teng Huang; Tzu-Hsin Huang; Ming-Chu Chiang; Yue-Cune Chang
Journal:  J Altern Complement Med       Date:  2016-03       Impact factor: 2.579

3.  Treatment of advanced non-small-cell lung cancer with Chinese herbal medicine by stages combined with chemotherapy.

Authors:  Zhen Ye Xu; Chang Juan Jin; Cai Cun Zhou; Zhong Qi Wang; Wei Dong Zhou; Hai Bin Deng; Ming Zhang; Wan Su; Xiao Yue Cai
Journal:  J Cancer Res Clin Oncol       Date:  2011-02-05       Impact factor: 4.553

4.  Prognostic factors of 112 elderly patients with advanced non-small cell lung cancer.

Authors:  Fanglan Ran; Qin Liu
Journal:  Pak J Med Sci       Date:  2022 Jul-Aug       Impact factor: 2.340

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.